June 19, 2018
Targovax granted EU Patent for mutant-RAS neoantigen platform 2nd generation product TG02
Media
June 18, 2018
Nexstim Plc SmartFocusTM TMS technology based therapy used across all university hospitals in Finland
June 17, 2018
Aprea Therapeutics Presents Results From Phase Ib/II Clinical Study of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) at the 2018 European Hematology Association (EHA) Annual Meeting in Stockholm
June 13, 2018
Nordic Nanovector Announces Archer-1 Trial of Betalutin® plus Rituximab in 2L Follicular Lymphoma Approved to Start in Norway
June 12, 2018
GenSight Biologics reports positive additional data from REVERSE Phase III clinical trial of GS010 for treatment of Leber Hereditary Optic Neuropathy (LHON)
June 12, 2018
Nordic Nanovector Announces Betalutin® has been granted Fast Track designation in the US for Follicular Lymphoma
June 11, 2018
Targovax strengthens focus on ONCOS oncolytic virus development program
June 11, 2018
Nordic Nanovector to present preclinical data demonstrating Betalutin® reverses resistance to anti-CD20 treatment in NHL cells
June 07, 2018
Onxeo Secures $7.5 Million of Non-dilutive Capital from SWK Holdings Corporation Through Sale of Rights related to Future Beleodaq® Royalties
June 01, 2018
BioClin Therapeutics Presents FIERCE-21: Phase 1b/2 Study of Docetaxel + B-701, a Selective Inhibitor of FGFR3, in Relapsed or Refractory Metastatic Urothelial Carcinoma at the American Society of Clinical Oncology (ASCO). Chicago, IL.